However the company does have a SGLT2 drug, Farxiga, which could have a similar CV profile to Jardiance. In March, AstraZeneca announced an analysis of real world data from more than 300,000 ...

The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin ... the study hoped to show similar benefits in post-AMI patients.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

GlobalData’s report assesses how Empagliflozin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks ... PTSR and likelihood of approval. Empagliflozin ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...

Pill for type 2 diabetes may control diabetic eye disease Boehringer Ingelheim and Eli Lilly’s oral diabetes drug Jardiance may keep diabetic eye disease from worsening in patients with type 2 ...

In each pair, one patient had received Jardiance, a pill from a class of drugs known as SGLT2 inhibitors, and the other received a DPP4 inhibitor such as Merck’s (MRK.N), opens new tab Januvia ...

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...

A study in the journal Addiction found that people addicted to alcohol who took Ozempic or similar medications had a 50% lower rate of binging on alcohol than those who did not. And people with ...